(Q33358735)

26 July 2017

title

Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies (English)

1 reference

26 July 2017

5

Razelle Kurzrock

1 reference

26 July 2017

2

Francis Giles

1 reference

Apostolia Maria Tsimberidou

26 July 2017

series ordinal

1

object named as

Apostolia-Maria Tsimberidou

1 reference

26 July 2017

Jorge Romaguera

3

1 reference

26 July 2017

Madeleine Duvic

series ordinal

4

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

100

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

574-580

1 reference

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

Alpha interferon in patients with progressive and/or recurrent Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

The role of interferon in the therapy of malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Combined modality therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Reporting outcomes in Hodgkin's disease and lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Retinoids and interferon: a new promising combination?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Stage IV CD30+ anaplastic large cell lymphoma: response to acitretin and interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Interferon therapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20009

7 January 2021

Identifiers

DOI

10.1002/CNCR.20009

1 reference

26 July 2017

1 reference